Study of inavolisib for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how well a drug called inavolisib works when combined with hormone therapy for people with a certain type of advanced breast cancer that has a specific gene change (PIK3CA). It aims to see if this treatment helps control the cancer in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced breast cancer that is HR-positive and HER2-negative.
- Your tumor has a specific gene change called PIK3CA.
- You have started treatment with inavolisib plus hormone therapy, with or without a CDK4/6 inhibitor.
- You are not participating in another clinical trial at the same time.
- You do not have another active cancer that needs treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
This study tests a new drug called inavolisib for people with early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding this drug to standard hormone therapy is safe and effective before surgery.
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
This trial tests a combination of three targeted therapies (inavolisib, ribociclib, and fulvestrant) in people with a specific type of advanced breast cancer that has a PIK3CA genetic change. The goal is to see if this new combination can shrink tumors or slow cancer growth, potentially offering a new option before other treatments are needed.
This trial combines two or three drugs (inavolisib, fulvestrant, and sometimes palbociclib) to treat hormone receptor positive, HER2 negative advanced breast cancer that has a PIK3CA mutation. The goal is to find out if this combination is safe and effective for people who also have type 2 diabetes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.